These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 27413251)

  • 21. [Measurement of fecal hemoglobin-haptoglobin complex as a new diagnostic tool of lower gastrointestinal tract diseases].
    Meguro T
    Hokkaido Igaku Zasshi; 1994 Jul; 69(4):995-1009. PubMed ID: 7959604
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Detection of colorectal neoplasms by the highly sensitive hemoglobin-haptoglobin complex in feces.
    Sieg A; Thoms C; Lüthgens K; John MR; Schmidt-Gayk H
    Int J Colorectal Dis; 1999 Dec; 14(6):267-71. PubMed ID: 10663892
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Validation of Faecal Pyruvate Kinase Isoenzyme Type M2 (Faecal M2PK Quick) Test in Detection of Colorectal Adenoma and Adenocarcinoma Among High-Risk Malaysian Population.
    Mohd Suan MA; Ng YZ; Henry GF; Md Said R; Kollanthavelu S; Mustapha MI; Hoe CH; Lee CK; Rajamanickam P; Ismail I; Chan HK; Abu Hassan MR
    Asian Pac J Cancer Prev; 2023 Sep; 24(9):3183-3186. PubMed ID: 37774070
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diagnostic accuracy of fecal calprotectin for screening patients with colorectal cancer: A meta-analysis.
    Ye X; Huai J; Ding J
    Turk J Gastroenterol; 2018 Jul; 29(4):397-405. PubMed ID: 30249553
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risk stratification of symptomatic patients suspected of colorectal cancer using faecal and urinary markers.
    Widlak MM; Neal M; Daulton E; Thomas CL; Tomkins C; Singh B; Harmston C; Wicaksono A; Evans C; Smith S; Savage RS; Covington JA; Arasaradnam RP
    Colorectal Dis; 2018 Dec; 20(12):O335-O342. PubMed ID: 30248228
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Proteins in stool as biomarkers for non-invasive detection of colorectal adenomas with high risk of progression.
    Komor MA; Bosch LJ; Coupé VM; Rausch C; Pham TV; Piersma SR; Mongera S; Mulder CJ; Dekker E; Kuipers EJ; van de Wiel MA; Carvalho B; Fijneman RJ; Jimenez CR; Meijer GA; de Wit M
    J Pathol; 2020 Mar; 250(3):288-298. PubMed ID: 31784980
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A pilot study on faecal MMP-9: a new noninvasive diagnostic marker of colorectal cancer.
    Annaházi A; Ábrahám S; Farkas K; Rosztóczy A; Inczefi O; Földesi I; Szűcs M; Rutka M; Theodorou V; Eutamene H; Bueno L; Lázár G; Wittmann T; Molnár T; Róka R
    Br J Cancer; 2016 Mar; 114(7):787-92. PubMed ID: 26908323
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diagnostic accuracy of faecal biomarkers in detecting colorectal cancer and adenoma in symptomatic patients.
    Widlak MM; Thomas CL; Thomas MG; Tomkins C; Smith S; O'Connell N; Wurie S; Burns L; Harmston C; Evans C; Nwokolo CU; Singh B; Arasaradnam RP
    Aliment Pharmacol Ther; 2017 Jan; 45(2):354-363. PubMed ID: 27910113
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy.
    von Roon AC; Karamountzos L; Purkayastha S; Reese GE; Darzi AW; Teare JP; Paraskeva P; Tekkis PP
    Am J Gastroenterol; 2007 Apr; 102(4):803-13. PubMed ID: 17324124
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fecal pyruvate kinase-M2 (tumor M2-PK) measurement: a new screening concept for colorectal cancer.
    Ewald N; Schaller M; Bayer M; Akinci A; Bretzel RG; Kloer HU; Hardt PD
    Anticancer Res; 2007; 27(4A):1949-52. PubMed ID: 17649802
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of a novel fecal marker--fecal tumor pyruvate kinase type M2 (M2-PK) with fecal calprotectin in patients with inflammatory bowel disease: a prospective study.
    Shastri YM; Povse N; Schröder O; Stein J
    Clin Lab; 2008; 54(9-10):389-90. PubMed ID: 19097497
    [No Abstract]   [Full Text] [Related]  

  • 32. [Chemical or immunological tests for the detection of fecal occult blood in colorectal cancer screening?].
    Quintero E
    Gastroenterol Hepatol; 2009 Oct; 32(8):565-76. PubMed ID: 19577340
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Volatile organic compounds in breath can serve as a non-invasive diagnostic biomarker for the detection of advanced adenomas and colorectal cancer.
    van Keulen KE; Jansen ME; Schrauwen RWM; Kolkman JJ; Siersema PD
    Aliment Pharmacol Ther; 2020 Feb; 51(3):334-346. PubMed ID: 31858615
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A multicenter prospective study of immunochemical fecal occult blood testing for colorectal cancer detection.
    Lohsiriwat V; Thavichaigarn P; Awapittaya B
    J Med Assoc Thai; 2007 Nov; 90(11):2291-5. PubMed ID: 18181309
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of integrin alpha 6 transcripts in a stool mRNA assay for the detection of colorectal cancers at curable stages.
    Beaulieu JF; Herring E; Kanaoka S; Tremblay É
    Oncotarget; 2016 Mar; 7(12):14684-92. PubMed ID: 26895101
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hypermethylation of SFRP2 as a potential marker for stool-based detection of colorectal cancer and precancerous lesions.
    Huang Z; Li L; Wang J
    Dig Dis Sci; 2007 Sep; 52(9):2287-91. PubMed ID: 17410438
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diagnostic value of fecal calprotectin as a screening biomarker for gastrointestinal malignancies.
    Khoshbaten M; Pishahang P; Nouri M; Lashkari A; Alizadeh M; Rostami-Nejad M
    Asian Pac J Cancer Prev; 2014; 15(4):1667-70. PubMed ID: 24641386
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunochemical fecal occult blood testing is equally sensitive for proximal and distal advanced neoplasia.
    de Wijkerslooth TR; Stoop EM; Bossuyt PM; Meijer GA; van Ballegooijen M; van Roon AH; Stegeman I; Kraaijenhagen RA; Fockens P; van Leerdam ME; Dekker E; Kuipers EJ
    Am J Gastroenterol; 2012 Oct; 107(10):1570-8. PubMed ID: 22850431
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cumulative evaluation of a quantitative immunochemical fecal occult blood test to determine its optimal clinical use.
    Rozen P; Comaneshter D; Levi Z; Hazazi R; Vilkin A; Maoz E; Birkenfeld S; Niv Y
    Cancer; 2010 May; 116(9):2115-25. PubMed ID: 20186820
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sensitivity and specificity of faecal tumour M2 pyruvate kinase for detection of colorectal adenomas in a large screening study.
    Haug U; Hundt S; Brenner H
    Br J Cancer; 2008 Jul; 99(1):133-5. PubMed ID: 18542075
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.